McNicoll Lewis & Vlak Starts INN, LHO, HST, BEE, AHT, HT at Buy, HOT, MAR, DRH, SHO, HPT at Hold
Tweet Send to a FriendGet Alerts INN Hot Sheet
Price: $9.62 --0%
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
6 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade INN Now!
McNicoll Lewis & Vlak's Ryan Meliker initiated coverage on the following stocks in the Hotels and Motels/REIT sector:
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
- Summit Hotel Properties (NYSE: INN) with a Buy rating and a $10 price target
- LaSalle Hotel (NYSE: LHO) with a Buy rating and a $32 price target
- Host Hotels (NYSE: HST) with a Buy rating and a $18 price target
- Strategic Hotel Properties (NYSE: BEE) with a Buy rating and a $7.50 price target
- Ashford Hospitality (NYSE: AHT) with a Buy rating and a $10 price target
- Hersha Hospitality Trust (NYSE: HT) with a Buy rating and a $6 price target
- Starwood Hotels & Resorts (NYSE: HOT) with a Hold rating and a $61 price target
- Marriott (NYSE: MAR) with a Hold rating and a $41 price target
- DiamondRock (NYSE: DRH) with a Hold rating and a $11 price target
- Sunstone Hotel Investors (NYSE: SHO) with a Hold rating and a $11 price target
- Hospitality Properties Trust (NYSE: HPT) with a Hold rating and a $25 price target
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Morgan Stanley Starts Western Union Co. (WU) at Equalweight
- Maxim Group Starts Teva Pharma (TEVA) at Buy
Create E-mail Alert Related Categories
New CoverageLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

